Wicab

Executive Summary

Wicab, Inc. is a privately held medical device company based in Middleton, Wisconsin, pioneering sensory substitution technology originally developed by Dr. Paul Bach-y-Rita. The company's core product, the BrainPort V100, is an FDA-approved assistive device that translates visual information into electrical pulses on the tongue, enabling blind and visually impaired individuals to perceive shapes, motion, and obstacles. With a lean team of 1-10 employees, Wicab has successfully commercialized a unique non-invasive solution that leverages neuroplasticity to bypass damaged sensory pathways. The company's technology has been validated through clinical studies and is positioned in the growing neurostimulation and assistive device market, estimated to reach billions globally as aging populations and sensory impairments rise. Despite its innovative platform, Wicab faces challenges in scaling adoption due to limited awareness, a relatively high device cost, and competition from emerging visual prosthetic technologies. The company is well-positioned to expand its indications beyond blindness, potentially addressing balance disorders or other sensory deficits through its tongue-based interface. As a small player with a disruptive technology, Wicab's future growth hinges on strategic partnerships, funding for clinical expansion, and commercial traction. With its approved product and ongoing R&D, Wicab represents a high-risk, high-reward opportunity in the neurorehabilitation space.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval for Next-Generation BrainPort Device60% success
• H1 2027Strategic Partnership or Licensing Deal with Major MedTech Firm40% success
• Q2 2026Publication of Clinical Trial Results for Balance Disorder Indication70% success